A new trading day began on Friday, with MaxCyte Inc (NASDAQ: MXCT) stock price down -2.33% from the previous day of trading, before settling in for the closing price of $1.29. MXCT’s price has ranged from $1.25 to $5.20 over the past 52 weeks.
During the last 5-year period, the sales drop of Healthcare Sector giant was -11.37%. Meanwhile, its annual earnings per share averaged 0.22%. With a float of $98.66 million, this company’s outstanding shares have now reached $106.64 million.
MaxCyte Inc (MXCT) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Medical Devices Industry. The insider ownership of MaxCyte Inc is 7.51%, while institutional ownership is 70.23%. The most recent insider transaction that took place on Jun 25 ’25, was worth 22,378. In this transaction Director of this company sold 10,684 shares at a rate of $2.09, taking the stock ownership to the 39,893 shares. Before that another transaction happened on Aug 13 ’25, when Company’s CHIEF FINANCIAL OFFICER bought 50,000 for $1.29, making the entire transaction worth $64,500. This insider now owns 161,811 shares in total.
MaxCyte Inc (MXCT) Recent Fiscal highlights
In its latest quarterly report, released on 12/31/2024, the company reported earnings of -0.1 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.06 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 0.22% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 21.74% during the next five years compared to -11.37% drop over the previous five years of trading.
MaxCyte Inc (NASDAQ: MXCT) Trading Performance Indicators
Here are MaxCyte Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 7.27. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.90.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.43, a number that is poised to hit -0.08 in the next quarter and is forecasted to reach -0.27 in one year’s time.
